Trials / Terminated
TerminatedNCT03752242
Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.
An Exploratory Trial to Evaluate the Clinical Effectiveness of a Topical Application of BMX-010 in Subjects With Acne Vulgaris.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- BioMimetix JV, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts.
Detailed description
Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug in patients with Acne. Up to 60 subjects will be enrolled in this part. Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo in patients with Acne. Up to 150 subjects will be enrolled in this part. In both parts, adult subjects with Acne will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMX-010 0.3% | Safety and efficacy of BMX-010 in topical treatment of acne. |
Timeline
- Start date
- 2019-01-03
- Primary completion
- 2020-08-31
- Completion
- 2020-08-31
- First posted
- 2018-11-23
- Last updated
- 2023-09-21
- Results posted
- 2023-09-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03752242. Inclusion in this directory is not an endorsement.